Clinical Trials Browser

Has results × Carcinoma, Renal Cell × Erlotinib Hydrochloride × Clear all

NCT01130519 2025-02-21

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Phase 2 Completed

83 enrolled 17 charts

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1 Terminated

29 enrolled 19 charts

EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT01688973 2019-01-03

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

55 enrolled 16 charts

Carcinoma, Renal Cell

NCT00425386 2017-05-03

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 2 Completed

60 enrolled 10 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00353301 2014-04-14

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

Phase 2 Completed

25 enrolled 9 charts

Carcinoma, Renal Cell

NCT00045487 2014-01-27

OSI-774

Phase 2 Completed

41 enrolled 7 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00193258 2013-01-31

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Phase 1/2 Completed

94 enrolled 7 charts

Carcinoma, Renal Cell